LIFECORE BIOMEDICAL, INC. \DE\
For the period ended Feb 23, 2025. Filed Apr 3, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Feb 23, 2025 · Filed Apr 3, 2025
LFCR$6.370.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Accrued expenses and other liabilities
- Accrued expenses and other current liabilities
The following table presents the components of accrued expenses and other current liabilities:
| February 23,2025 | May 26,2024 | |
|---|---|---|
| Accrued compensation | $5,843 | $6,165 |
| Accrued payable to Series A preferred stockholders | 4,377 | 3,471 |
| Accrued customer pass-through expenditures | 2,101 | 3,509 |
| Accrued professional fees | 1,798 | 830 |
| Contract liabilities, related party | 1,750 | 1,025 |
| Current portion of debt | 930 | 943 |
| Contract liabilities | 815 | 1,088 |
| Other | 2,131 | 1,544 |
| Accrued expenses and other current liabilities | $19,745 | $18,575 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.